Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.4K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.4K
Hypersensitivities01:30

Hypersensitivities

7.2K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
7.2K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

947
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
947
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

606
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
606

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PDGF-BB as a potential biomarker for early diagnosis of postpartum hemorrhage.

Frontiers in global women's health·2026
Same author

Subsequent Malignant Neoplasms in Childhood Cancer Survivors: Identifying Risks and Screening Recommendations.

Hematology/oncology clinics of North America·2026
Same author

Evaluating Uncommon Inflammatory Markers in Common Pediatric Bacterial Infections.

WMJ : official publication of the State Medical Society of Wisconsin·2026
Same author

Impact of a Multidisciplinary Cancer Predisposition Program on Adherence With Screening Guidelines for Patients With Cancer Predisposition Syndromes.

Journal of pediatric hematology/oncology·2026
Same author

Stakeholder Perspectives on Applying for the Fresh Fruit and Vegetable Program in Low-Resource Schools.

The Journal of school health·2026
Same author

The latent organization of white matter microstructure and its relation to fluid intelligence.

Imaging neuroscience (Cambridge, Mass.)·2026

Related Experiment Video

Updated: Jan 18, 2026

Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity
10:22

Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity

Published on: September 16, 2011

34.1K

Asparaginase Premedication With Hydrocortisone Decreases Hypersensitivity Reactions.

Ryan Guerrettaz1, Megan Wegter2, Melodee Liegl3

  • 1Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin.

Journal of Pediatric Hematology/Oncology
|September 10, 2025
PubMed
Summary

Adding hydrocortisone to premedication significantly reduces hypersensitivity reactions (HSR) to pegylated E. coli asparaginase (PEG). This 3-drug regimen lowers HSR rates, improving leukemia and lymphoma treatment tolerance.

Keywords:
asparaginasehypersensitivity reactionsleukemiapediatrics

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.4K
Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.3K

Related Experiment Videos

Last Updated: Jan 18, 2026

Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity
10:22

Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity

Published on: September 16, 2011

34.1K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.4K
Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.3K

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Pegylated E. coli asparaginase (PEG) is crucial for leukemia/lymphoma treatment but causes hypersensitivity reactions (HSR).
  • HSR often necessitates switching to Erwinia asparaginase (ERW), increasing patient burden.
  • Current premedication with diphenhydramine and famotidine shows variable efficacy in preventing HSR to PEG.

Purpose of the Study:

  • To evaluate the efficacy of adding hydrocortisone to a standard 2-drug premedication regimen for preventing HSR to PEG.
  • To compare HSR and infusion reaction (IR) rates between patients receiving a 2-drug versus a 3-drug premedication regimen.

Main Methods:

  • Retrospective analysis of patients with lymphoid malignancies receiving frontline PEG.
  • Comparison of a 2-drug (diphenhydramine, famotidine) regimen group with a 3-drug (diphenhydramine, famotidine, hydrocortisone) regimen group.
  • Independent review and grading of HSRs and IRs using CTCAE v5.

Main Results:

  • The 3-drug regimen group (n=35) showed a significant decrease in HSR rates (11%) compared to the 2-drug group (n=50, 38%) (P=0.007).
  • Infusion reaction (IR) rates remained consistent between the groups (11% in both).
  • The addition of hydrocortisone led to a >25% reduction in HSR rates.

Conclusions:

  • Adding hydrocortisone to diphenhydramine and famotidine premedication effectively reduces HSR to IV PEG.
  • This strategy may improve treatment adherence and reduce the need for alternative therapies like ERW.
  • Further prospective studies are warranted to confirm these findings.